Soleno Therapeutics (SLNO) Free Cash Flow (2013 - 2026)
Soleno Therapeutics (SLNO) reported Free Cash Flow of $25.9 million for Q1 2026, up 179.2% year-over-year from $9.3 million in Q1 2025, and down 46.68% quarter-over-quarter from $48.6 million in Q4 2025.
Soleno Therapeutics (SLNO) Free Cash Flow (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Free Cash Flow data on file, last reported at $25.9 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at $25.9 million, up 179.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.4 million (up 217.75% YoY), and the FY2025 annual result was $46.7 million, up 167.41% from the prior year.
- Free Cash Flow eased to $25.9 million in Q1 2026 per SLNO's latest filing, from $48.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $48.6 million in Q4 2025 and troughed at -$32.8 million in Q1 2025.
- A 5-year average of -$2.5 million and a median of -$6.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 280.09% in 2024, then jumped 387.71% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$5.1 million in 2022, then slipped by 22.63% to -$6.3 million in 2023, then tumbled by 280.09% to -$24.0 million in 2024, then jumped by 302.7% to $48.6 million in 2025, then sank by 46.68% to $25.9 million in 2026.
- Business Quant data shows SLNO's Free Cash Flow at $25.9 million in Q1 2026, $48.6 million in Q4 2025, and $43.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 25.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.94 Mn |
| Mar 31, 2026 | 25.94 Mn |
| Dec 31, 2025 | 48.65 Mn |
| Dec 31, 2025 | 48.65 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Jun 30, 2025 | -12.66 Mn |
| Jun 30, 2025 | -12.66 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Dec 31, 2024 | -24.00 Mn |
| Dec 31, 2024 | -24.00 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Jun 30, 2024 | -17.66 Mn |
| Jun 30, 2024 | -17.66 Mn |
| Mar 31, 2024 | -12.54 Mn |
| Mar 31, 2024 | -12.54 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Dec 31, 2023 | -6.31 Mn |